Company / Return on Equity (ROE)
TransMedics Group, Inc. Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
40.2%
FY2025
5-year range
-65.2% / 40.2%
FY2021-FY2025
Trend
+159.3%
vs FY2024
Sector context
#6 of 147
Health Care
What the data says
Among 147 Health Care companies, TransMedics Group, Inc. is in the top 4% for return on equity (roe). Return on Equity (ROE) has increased for 4 consecutive years, from -65.2% in FY2021 to 40.2% in FY2025.
Based on SEC 10-K filings.
40.2% in FY2025 with a 5-year CAGR of +67.9%. Top quartile in the Health Care sector.
Improved from -18.2% to 40.2% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +59.6pp
- 5-Year Change
- +67.9pp
- 10-Year Change
- -
Sector benchmark
Top 4% in Health CareTop 4% of 147This company 40.2% Sector average -3.1%
▼
+1388.8% above sector average
Key checks
Key Insights
- TransMedics Group, Inc.'s return on equity (roe) has grown for 4 consecutive years.
- In FY2025, return on equity (roe) increased 159.3% year-over-year.
- Currently 43.3pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2021.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 40.2% | +159.3% |
| FY2024 | 15.5% | +185.0% |
| FY2023 | -18.2% | +5.7% |
| FY2022 | -19.3% | +70.3% |
| FY2021 | -65.2% | -135.5% |
| FY2020 | -27.7% | -64.4% |
| FY2019 | -16.8% | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026